KUALA LUMPUR, 26 February 2019 – Clinical Research Malaysia (CRM) inked two Memorandum of Understanding (MoU) with two prominent Singapore organizations in the field of clinical research. This will further pave the way for better Malaysia–Singapore collaborations in advancing drug development and research capabilities between both countries.
“We have embarked on completing the ecosystem for the Early Phase drug development work with CRM leading the way since 2016. It was a very proud moment today that these two prominent organizations have agreed to work with CRM and Institute of Medical Research (IMR) of the Ministry of Health on various projects in drug development including training of our doctors to be able to conduct early phase clinical trials,” said the Minister of Health and Chairman of CRM, YB Datuk Seri Dr. Dzulkefly Ahmad.
The MoU with the National University Hospital (Singapore) Pte Ltd (NUH) spells out support in the areas of clinical trial promotion, business development, networking opportunities, clinical trial operations, training as well as in feasibility assessments. Through this partnership CRM will work closely with NUH and potentially the rest of the entities under the National University Health System (NUHS) in training our clinicians with the knowledge and expertise in conducting early phase clinical trials. The initial focus of the collaboration will be in oncology clinical trials and masterclasses conducted by the National University Cancer Institute, Singapore (NCIS), which is part of the NUHS. Commenting on the MoU, Group Director of the NUHS Research Office and Director of NCIS, Prof. Chng Wee Joo added “Being involved in regional trial network is an important strategy for NCIS. Going beyond Singapore and establishing networks with our neighbours will put us in good stead in attracting more collaboration with the industry so that collectively we can make greater impact in clinical trials. Another important aspect of our academic strategy is to provide training in our areas of strength to the doctors in the regions. The current collaboration with CRM will fulfil both of these important objectives. We eagerly look forward to seeing the fruits of these collaborations in the next 1-2 years.”
CytoMed Therapeutics is a spinoff company from Singapore’s Agency for Science, Technology and Research (A*Star) and has been developing treatments to treat a wide range of cancers using the patient’s or donor’s immune cells. CytoMed Therapeutics will be partnering with the IMR, which is being represented in this MOU by CRM to conduct an immunotherapeutic preclinical study initially. As the project progresses further, this will open up possibilities for future studies that go beyond the preclinical stage into translational studies and clinical trials. Commenting on the MoU, Director of CytoMed Therapeutics, Mr Choo Chee Kong, “This collaboration between CytoMed Therapeutics and CRM and IMR will open doors for more cell therapy trials and treatment to come into Malaysia. Collaborating with IMR and CRM, we are looking forward to a first-in-human clinical trial for CAR- gamma delta-T cells in the world.”
The MoU was signed by the CEO of CRM, Dr. Akhmal Yusof, Group Director of the NUHS Research Office, Prof. Chng Wee Joo and Director of CytoMed Therapeutics Pte Ltd, Mr Choo Chee Kong. The signing of the MoU was witnessed by the Minister of Health, YB Datuk Seri Dr. Dzulkefly Ahmad, Secretary General of Health, YBhg. Dato’ Seri Dr. Chen Chaw Min, Director General of Health, YBhg. Datuk Dr. Noor Hisham Abdullah as well as Director of Institute of Medical Research, Dato Dr Fadzilah Kamaludin
With these MoUs, CRM has added Singapore to the network of global research partnership that it currently has working collaborations with, such as Japan, Taiwan, China, South Korea, United States, Switzerland and Canada to attract more sponsored research into the country.
A clear culmination of CRM’s growth and success is the opening of its new office at Level 26, Menara SuezCap, Kuala Lumpur which was officiated on the same day earlier by the Minister of Health and accreditation of ISO 9001:2015 it just received recently in January 2019.
About Clinical Research Malaysia
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to- end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.
About the National University Hospital
The National University Hospital (NUH) is a tertiary hospital and major referral centre with over 50 medical, surgical and dental specialties, offering a comprehensive suite of specialist care for adults, women and children. It is the only public hospital in Singapore to offer a paediatric kidney and liver transplant programme, in addition to kidney, liver and pancreas transplantation for adults.
The Hospital was opened on 24 June 1985 as Singapore’s first restructured hospital. Each year, the Hospital attends to more than one million patients.
As an academic health institution, patient safety and good clinical outcomes are the focus of the Hospital. It plays a key role in the training of doctors, nurses, allied health and other healthcare professionals. Translational research is pivotal in the Hospital’s three-pronged focus, and paves the way for new cures and treatment.
A member of the National University Health System, it is the principal teaching hospital of the NUS Yong Loo Lin School of Medicine and the NUS Faculty of Dentistry.
For more information about NUH, visit www.nuh.com.sg
About the National University Health System
The National University Health System (NUHS) is one of three public healthcare clusters in Singapore, and an integrated Academic Health System and Regional Health System that delivers value-driven, innovative and sustainable healthcare in Singapore.
Through collaborations with National University of Singapore (NUS) faculties, we are able to draw upon their academic, research and creative capabilities to develop solutions for existing and emerging health and healthcare needs.
As a Regional Health System, we work in close collaboration with community hospitals, general practitioners, family medicine clinics and other community partners to provide integrated care to the community.
With member institutions under one Academic Health System, NUHS creates synergies as a fully integrated cluster to provide seamless care, develop solutions for Singapore’s healthcare challenges and nurture the next generation of healthcare professionals.
- National University Hospital
- Ng Teng Fong General Hospital
- Jurong Community Hospital
- Alexandra Hospital
- Jurong Medical Centre
- National University Cancer Institute, Singapore
- National University Heart Centre, Singapore
- National University Centre for Oral Health, Singapore
- National University Polyclinics
- NUS Yong Loo Lin School of Medicine
- NUS Alice Lee Centre for Nursing Studies
- NUS Faculty of Dentistry
- NUS Saw Swee Hock School of Public Health, Singapore
For more information about NUHS, please visit www.nuhs.edu.sg.
About the National University Cancer Institute, Singapore
The National University Cancer Institute, Singapore (NCIS) offers a broad spectrum of cancer care and management covering both paediatric and adult cancers, with expertise in prevention, screening, diagnosis, treatment, rehabilitation and palliative care. The Institute’s strength lies in the multi-disciplinary approach taken to develop a comprehensive and personalised plan for each cancer patient and his or her family.
With several award-winning clinician-scientists and clinician-investigators, NCIS has an international reputation in translational research and clinical trials, providing patients with access to promising breakthroughs in cancer diagnostics, technology and therapies.
For more information about NCIS, please visit www.ncis.com.sg.
About CytoMed Therapeutics
Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers. CytoMed believes that “off-the-shelf” cancer immunotherapeutics will be the future of cancer immunotherapy through lowering cost and allowing access of therapy to the masses. For more information, please visit www.cytomed.sg.
Mr. Syed Hamzah Syed Noordin | firstname.lastname@example.org| +6(03) 7931 5566 (ext. 120)